BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Topics » Drugs » Monoclonal antibody

Monoclonal antibody
Monoclonal antibody RSS Feed RSS

Coronavirus spike protein
Infection

GB-0669, a novel MAb targeting the conserved S2 region of spike protein

Oct. 18, 2023
Researchers from Generate Biomedicines Inc. have detailed the discovery and preclinical characterization of GB-0669, a spike S2-targeted monoclonal antibody (MAb) being developed for the prophylaxis of SARS-CoV-2 infection. Machine learning models were used to identify MAbs targeting the conserved S2 stem helix and RBD class IV region of spike.
Read More
Art concept for monoclonal antibodies
Drug Design, Drug Delivery & Technologies

Salipro Biotech and Icosagen enter multitarget antibody research agreement

Oct. 11, 2023
Salipro Biotech AB and Icosagen AS have entered into a multitarget antibody research agreement for the discovery and characterization of monoclonal antibodies against several challenging membrane proteins.
Read More
Infection

Aerium licenses monoclonal antibodies against SARS-CoV-2

Oct. 5, 2023
Aerium Therapeutics Inc. has licensed and commenced development of three monoclonal antibodies (MAbs) with broad and potent activity against the predominant variants of SARS-CoV-2, including those containing the F456L mutation, such as EG.5.1. These antibodies could provide an option to protect immunocompromised populations from severe COVID-19.
Read More
SARS-CoV-2 illustration turns from blue to red
Infection

BARDA funding supports Vir’s development of monoclonal antibody and delivery solutions for COVID-19 and pandemic preparedness

Oct. 5, 2023
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response, has awarded Vir Biotechnology Inc. approximately $50 million in new funding to advance the development of novel monoclonal antibody (MAb) candidates and delivery solutions to widen the applicability of MAbs in COVID-19 and in pandemic preparedness and response.
Read More
Immuno-oncology

Pharmabcine’s anti-VISTA antibody PMC-309 receives Australian HREC clearance for phase I study in solid tumors

Sep. 19, 2023
Pharmabcine Inc. has received approval from the human research ethics committee (HREC) in Australia for a phase Ia/b trial of PMC-309, a monoclonal antibody against the human V-domain Ig suppressor of T-cell activation (VISTA) ligand.
Read More
Drug capsule spilling onto brain
Neurology/Psychiatric

FDA clears IND for ADEL-Y01 for Alzheimer’s disease

Sep. 15, 2023
The FDA has cleared an IND application for ADEL-Y01, being jointly developed by Oscotec Inc. and Adel Inc., for the treatment of Alzheimer’s disease. A phase Ia/b study will include healthy volunteers, and participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease.
Read More
Scientist looking in microscope, chemical structure concept image
Drug Design, Drug Delivery & Technologies

Biomarin outlines progress of preclinical pipeline

Sep. 13, 2023
Biomarin Pharmaceutical Inc. has reported progress across its research and development portfolio, including early-stage product candidates.
Read More
3D drawing of molecular structure of ricin
Substance Use & Poisoning

Antoxa and Swiftpharma collaborate to advance plant-made antibody against ricin exposure

Sep. 6, 2023
Antoxa Corp. and Swiftpharma BV have signed an exclusive collaboration agreement to support the development and commercialization of a plant-made monoclonal antibody against ricin exposure.
Read More
Scanning electron micrograph of Lassa virus budding off a cell.
Infection

huMAb combination broadly protects primates against most LASV strains after viral exposure

Aug. 23, 2023
Most of the West African population is at risk of infection with Lassa virus (LASV), which leads to Lassa fever that causes thousands of deaths every...
Read More
Pancreatic cancer cells.
Immuno-oncology

FDA awards orphan drug designation to Canariabio's MAb-AR20.5 for pancreatic cancer

Aug. 22, 2023
Canariabio Inc.'s MAb-AR20.5 has been awarded orphan drug designation by the FDA for pancreatic cancer. MAb-AR20.5 is an IgG1k type murine monoclonal antibody that binds specifically to the circulating and tumor-associated antigen (MUC1) expressed on pancreatic cancer cells.
Read More
Previous 1 2 … 27 28 29 30 31 32 33 34 35 36 37 38 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing